Gladwyne Partners

Gladwyne Partners was a venture capital firm based in New York that focused on investing in companies across the retail, medical, and technology sectors. The firm's primary line of business involved trust management services, enabling them to provide strategic financial support to their portfolio companies. Through these investments, Gladwyne Partners aimed to foster growth and innovation within these industries.

2 past transactions

The Electric Sheep

Series A in 2007
The Electric Sheep Company specializes in creating web-enabled social and virtual world experiences, focusing on strategy, design, production, and technology. Established in 2005, the company has collaborated with numerous prominent brands and media companies to develop engaging consumer virtual experiences. Its notable projects include the development of 3-D properties and platforms such as WebFlock, which facilitates social interaction, media consumption, and gameplay within a visual environment, as well as Second Life, an online society that allows users to create and interact with digital characters in a crafted virtual world. The Electric Sheep Company has partnered with a diverse array of clients, including major names in entertainment, technology, and consumer goods.

Micell Technologies

Venture Round in 2002
Micell Technologies is a biomedical device company that specializes in the development of interventional cardiology systems for vascular drug delivery. Founded in 1995 and based in North Carolina, the company offers a range of innovative products, including the MiStent, a drug-eluting stent that combines the therapeutic benefits of sirolimus with the characteristics of a bare-metal stent. In addition to MiStent, Micell develops drug-coated balloons for delivering sirolimus to arterial walls during procedures such as percutaneous transluminal angioplasty and stent implantation, as well as bioresorbable scaffolds and peripheral drug-eluting stents. The company's advanced technology utilizes supercritical fluid processes to optimize drug release and enhance healing, aiming to improve safety and clinical outcomes for patients with cardiovascular diseases. Micell also provides clinical trials and health economics services to support its product development and market integration.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.